Search
Displaying 241–250 of 556 for “Retinitis pigmentosa”
-
Beacon Stories
“My husband and I have not been able to be significant Foundation supporters during our lifetimes,” she said, “but I would be honored to leave this gift as part of my legacy.”
-
Beyond Labels: The Inspiring Journey of a Refsum Disease Advocate
Beacon StoriesAfter years of seeking answers, Alan Gunzburg was formally diagnosed with Refsum disease, a rare genetic disorder. Drawing on his unique journey, Alan sheds light on the obstacles he’s faced and how his experience motivated him to make a positive impact in the lives of others.
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
Coave Reports Encouraging Phase 1/2 Clinical Trial Results for PDE6B Gene Therapy
Research NewsThe company is expanding the trial to enroll younger patients with less advanced disease
-
Research News
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
-
Birding Blind: Identifying Birds by Song
Beacon StoriesMartha Steele has been birding for over 30 years, but the way in which she birds has changed over time. Martha has Usher syndrome, with her central vision declining rapidly in the early 2000s and receiving her first cochlear implant in 2010. Now she birds entirely by ear and has learned the songs of about 150 bird species.
-
Eye on the Cure Podcast | Episode 39: Paul Bernstein, MD, PhD
Eye on the CureJanuary 20, 2023. Paul Bernstein, MD, PhD, from the Moran Eye Center, University of Utah, and a member of the Foundation’s Scientific Advisory Board talks to host Ben Shaberman about his clinical practice for retinal disease patients
-
Retinal Research Community Loses Beloved Pioneer Sam Jacobson
Beacon StoriesHis many contributions included pivotal work that led to LUXTURNA
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
Research NewsThe LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
.png)
